# Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

> **NCT00623064** · PHASE1 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 18 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter

## Interventions

- **DRUG:** cisplatin
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** lapatinib ditosylate
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00623064
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-06
- **Final completion:** 2012-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623064, "Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00623064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*